top of page
Search Results

251 items found for "drug repurposing"

  • The landscape of cancer-rewired GPCR signaling axes

    ., muscarinic, adenosine, 5-hydroxytryptamine, and chemokine receptors, are the targets of multiple drugs displaying anti-growth effects in large-scale, cancer cell drug screens, which we further validated. Silvio Gutkind , Francesco Raimondi Tags GPCR , cancer , cancer cell lines , cell-cell communication , drug repurposing , personalized medicine , signaling network , survival analysis , transcriptomics . Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs

  • Applying Pharmacology to Drug Discovery

    Applying Pharmacology to Drug Discovery Dr. Pharmacology is a unique discipline and is critical to drug discovery. Registrants will learn: Methods to characterize the three major drug types. What makes each drug type unique to therapeutic pharmacology? 3. Essential information is needed to characterize a drug's profile aimed at therapy.

  • Principles of Pharmacology in Drug Discovery II

    Principles of Pharmacology in Drug Discovery II Dr. course continues with the basics learned in Course 1 and extends the ideas to apply GPCR utilization in drug New ligands and new GPCR behaviors that produce unique drug profiles (i.e. intracellular ligands and Lecture 2: Drug Disposition in Physiological Tissues as a Therapeutic Variable. Lecture 4: Unconventional GPCR Ligands as Drugs.

  • Principles of Pharmacology in Drug Discovery I

    Principles of Pharmacology in Drug Discovery I Techniques for Effective Lead Optimization of Candidate Candidate Molecules GPCRs have been and arguably still are the most prolific and fertile therapeutic drug receive a comprehensive understanding of the unique science of pharmacology and how it can describe drug To help registrants understand the value of Pharmacology in the drug discovery process. Pharmacology in Drug Discovery and Development (3rd ed.) T.P.

  • Principles of Pharmacology in Drug Discovery II

    Principles of Pharmacology in Drug Discovery II Advanced Methods for the Optimization of Candidate Selection New ligands and new GPCR behaviors that produce unique drug profiles (i.e. intracellular ligands and November 7th: Drug Disposition in Physiological Tissues as a Therapeutic Variable. November 21st: Unconventional GPCR Ligands as Drugs. Pharmacology in Drug Discovery and Development (3rd ed.)

  • Principles of Pharmacology in Drug Discovery I

    Principles of Pharmacology in Drug Discovery I Dr. Candidate Molecules GPCRs have been and arguably still are the most prolific and fertile therapeutic drug receive a comprehensive understanding of the unique science of pharmacology and how it can describe drug Lecture 2: Drug Affinity: Measurement of Antagonism (Binding and Function) / Classifying Antagonists. My interests are in receptor theory, pharmacology applied to drug discovery and allosteric protein function

  • Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia

    < GPCR News < GPCRs in Oncology and Immunology Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia Published date June 14, 2024 Abstract " Purpose: The inherent genetic heterogeneity of acute signatures for drug response prediction, and provide resources to the research community. Experimental design: We performed targeted sequencing, high-throughput drug screening, and single-cell to some drug classes, such as MEK inhibitors for RAS-mutated leukemia.

  • S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia

    Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs in chronic myeloid leukemia (CML) treatment, is accompanied by discontinuation challenges owing to drug compounds-ampelopsin, ellagic acid, colchicine, epigallocatechin-3-gallate, cucurbitacin B, and evodin-as potential drug Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs

  • Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer: Expression in Fallopian Tubes and Drug Design

    Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer: Expression in Fallopian Tubes and Drug Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs

  • Ep 71 with Dr. Jean Martin Beaulieu

    research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug and drug development technology.

  • Interrogating Multiscale Receptors Functions in Space

    research is aimed at understanding how cellular and molecular mechanisms regulated by psychoactive drugs In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia Work by the Beaulieu Lab has demonstrated that mood stabilizer drugs (e.g. lithium) used for bipolar mechanisms regulated by dopamine receptors, thus providing a framework to understand how different drug and drug development technology.

  • Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways

    Part I described the proteomic workflow and drug effects on the upstream portion of the SPD model related Here we describe drug effects on pathways associated with cell cycle, DNA damage response (DDR), and Drug combination effects on protein changes in the cell cycle- and apoptosis pathways contribute to the This approach provides a quantitative mechanistic framework for evaluating drug-drug interactions in Li , Xiaomeng Shen , Jun Qu , Robert M Straubinger , William J Jusko Tags Systems Pharmacodynamic , drug

  • Ep 118 with Dr. David Sykes

    Sykes, BSc Hons Pharmacology, MSc Molecular Biology and Biochemistry, PhD in Molecular Pharmacology & Drug David has over 20+ years of experience working in a drug discovery environment mainly in a specialist 2014 David joined the University of Nottingham and began a part-time PhD in Molecular Pharmacology and Drug compounds (and chemical fragments) and the use of purified receptor/ effector proteins as tools for drug

  • Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem

    Molecular tools and biosensors directed at AGPCR signaling and function The NTF Release Sensor Approach for Drug BRET-Based Platform for Comprehensive Profiling of adhesion GPCR Signaling and Pharmacology-Enabling Drug for Human Adhesion GPCRs Stephanie Häfner Abstract "G Protein-coupled receptors (GPCRs) are common drug targets, yet no approved drugs exist for the Adhesion G Protein-coupled receptors (aGPCRs or ADGRs). of an N-terminal fragment (NTF) and a C-terminal fragment (CTF), posing challenges for traditional drug

  • Ep 34 with Dr. Brian Arey

    He currently leads a team that provides a mechanistic understanding of small molecule drug candidates Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular , biochemical, cellular, and in vivo assessment of drug candidates in many different physiological systems He continues to pioneer in drug discovery studying GPCRs and other target classes.

  • Ep 35 with Dr. Brian Arey

    He currently leads a team that provides a mechanistic understanding of small molecule drug candidates Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular , biochemical, cellular, and in vivo assessment of drug candidates in many different physiological systems He continues to pioneer in drug discovery studying GPCRs and other target classes.

  • Ep 150 with Dr GPCR Team

    interested in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the As a young researcher fascinated by chemokine receptors, molecular pharmacology, drug discovery, and University, John plays a pivotal role in the pharmacological screening of compounds for a commercial drug Driven by a passion for advancing drug development, John is committed to leveraging his expertise to

  • Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation

    (GPCRs) have been investigated for active targeting with nanomedicines such as antibody-conjugated drugs and drug-loaded nanoparticles, highlighting a neglected potential to develop personalised treatment. cancer biopsies, matched with personalised GPCR-targeted nanomedicines, for the delivery of lethal drugs Carmela Ricciardelli, Martin K Oehler, Anton Blencowe, Sanjay Garg, Katherine Pillman, Hugo Albrecht Tags Drug Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs

  • Ep 146 with Dr Michael Feigin

    cancer pathogenesis, using mouse models, three-dimensional cell culture and computational approaches to drug , and 2) dysregulation of the pancreatic tumor microenvironment by commonly prescribed anti-anxiety drugs drugs on cancer-associated fibroblasts and discussed their work on gene regulation in fibroblasts. Mike also shared about a drug that targets an enzyme involved in mRNA cleaving, which has been found Cytokine Inhibition, Collaboration, and Anti-Anxiety Drug Research Mike discussed the ongoing research

  • Interplay between G protein-coupled receptors and nanotechnology

    Although GPCRs are the molecular targets of the majority of marketed drugs, the poor pharmacokinetics encapsulate GPCR ligands to assemble synthetic nano-GPCRs to overcome their obstacles, robustly elevating drug It will provide a fundamental platform for developing powerful and safe GPCR-targeted drugs and nanoparticle STATEMENT OF SIGNIFICANCE: GPCRs as molecular targets for the majority of marketed drugs are naturally Jiang , Yuke Li , Xiujuan Fu , Yue Wu , Rujing Wang , Mengnan Zhao , Canquan Mao , Sanjun Shi Tags Drug

  • Ep 137 with Dr. Josh Pottel

    self-sustaining computational chemistry service provider, developing its own software for application in various drug I have extensive training in computer-aided drug design. training as a chemist and as an entrepreneur to grow a sustainable service and software provider in drug

  • Advanced data analysis for GPCR pharmacology

    courses Main objectives: Learning how to perform advanced GPCR pharmacology data analysis in support of drug communicate GPCR pharmacology data analysis to a high level, as well as expertise that can be applied in drug science and academic organizations in understanding and applying in vitro pharmacology data to advance drug Sam specializes in kinetic analysis of drug action and is known for applying binding and signaling kinetics industry for 15 years at Neurocrine Biosciences, guiding the in vitro biology efforts for numerous drug

  • Exploration of prognostic and treatment markers in hepatocellular carcinoma via GPCR-related genes analysis

    protein-coupled receptors (GPCRs), the biggest family of signaling receptors, account for 34 % of all the drug targets approved by the Food and Drug Administration (FDA). Sensitivity to immunotherapy and common antitumor drugs was predicted via the database Genomics of Drug Distinct sensitivity to chemotherapeutic drugs was observed. Industry News Adhesion GPCRs GPCR Events, Meetings, and Webinars Reviews, GPCRs, and more GPCR Binders, Drugs

  • Session IX / Technology capsule: Light on aGPCR signaling and function | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem

    Technology capsule: Light on aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing monoclonal antibody drugs against GPCRs and other multi-pass transmembrane developing highly specific antibodies for complex targets, with implications for overcoming challenges like drug

  • Ep 152 with Dr Arthur Christopoulos

    His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and 2021 he was elected a Fellow of the Australian Academy of Science for his seminal contributions to drug Next steps - Arthur will continue to collaborate with other researchers and drug companies to advance The discussion underscored the potential of allosteric modulators as drugs, despite challenges in the They also discussed the potential of certain drugs, like flumazenil, as 'nails' or compounds that could

  • Ep 37 with Dr. Samuel Hoare

    with numerous pharma and biotechs in understanding and applying in vitro pharmacology data to advance drug He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development He guided the in vitro biology efforts of the company for numerous drug discovery campaigns.

  • Ep 109 with Dr. Katarina Nemec

    engaged in researching molecular mechanisms that govern human (patho-)physiology and their interplay with drugs I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets to create drugs with fewer adverse effects.

  • Ep 98 with Dr. GPCR Team

    As a young researcher fascinated by chemokine receptors, molecular pharmacology, drug discovery, and interested in using G-Protein Coupled Receptors (GPCRs), that control virtually everything in the body, as drug GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the

bottom of page